Boston Partners reduced its position in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 3.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,948,535 shares of the medical research company's stock after selling 103,155 shares during the quarter. Boston Partners owned approximately 3.63% of Labcorp worth $908,741,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Allied Private Wealth LLC acquired a new stake in Labcorp in the second quarter worth about $33,000. William Mack & Associates Inc. acquired a new stake in shares of Labcorp during the third quarter worth $42,000. Pathway Financial Advisers LLC acquired a new stake in Labcorp during the 3rd quarter worth about $43,000. Jones Financial Companies Lllp acquired a new position in Labcorp in the 2nd quarter worth approximately $58,000. Finally, Ancora Advisors LLC purchased a new position in shares of Labcorp during the second quarter valued at $67,000. Institutional investors own 95.94% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on LH. Leerink Partners set a $410.00 target price on shares of Labcorp in a research report on Wednesday, October 28th. Deutsche Bank reiterated a "hold" rating and issued a $355.00 target price on shares of Labcorp in a research note on Thursday, October 29th. JPMorgan Chase & Co. upped their price target on Labcorp from $330.00 to $360.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Piper Sandler increased their target price on shares of Labcorp from $300.00 to $309.00 and gave the company a "neutral" rating in a research note on Tuesday, August 4th. Finally, HSBC upgraded shares of Labcorp from a "hold" rating to a "buy" rating and set a $410.00 price target on the stock in a research note on Thursday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, Labcorp currently has an average rating of "Moderate Buy" and a consensus target price of $369.08.
View Our Latest Analysis on Labcorp
Labcorp Stock Up 0.7%
NYSE LH opened at $370.68 on Thursday. Labcorp Holdings Inc. has a one year low of $245.00 and a one year high of $375.10. The firm has a market cap of $30.10 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 2.08 and a beta of 0.86. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.41 and a quick ratio of 1.22. The stock's 50 day simple moving average is $332.38 and its 200 day simple moving average is $294.09.
Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The business had revenue of $3.81 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the previous year, the business posted $4.18 earnings per share. The firm's revenue for the quarter was up 6.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Labcorp Holdings Inc. will post 18.51 earnings per share for the current fiscal year.
Labcorp Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be issued a $0.72 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 annualized dividend and a yield of 0.8%. Labcorp's dividend payout ratio (DPR) is currently 23.63%.
Insider Buying and Selling at Labcorp
In related news, EVP Bryan T. Vaughn sold 306 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $353.70, for a total value of $108,232.20. Following the sale, the executive vice president directly owned 6,845 shares in the company, valued at $2,421,076.50. This trade represents a 4.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 365 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $372.58, for a total transaction of $135,991.70. Following the completion of the sale, the executive vice president owned 6,590 shares in the company, valued at approximately $2,455,302.20. This trade represents a 5.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,749 shares of company stock worth $1,377,699 in the last 90 days. Corporate insiders own 0.84% of the company's stock.
Labcorp Company Profile
(
Free Report)
Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Labcorp, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.
While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.